Sun Pharma Advanced Research Company Limited
NSE: SPARC · Pharmaceuticals
Snapshot
Unlock Sun Pharma Advanced Research Company Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sun Pharma Advanced Research Company Limited (SPARC) is a biopharmaceutical firm focused on the research and development of new chemical and biological entities, as well as reformulated pharmaceutical products. The company specialises in therapeutic areas including oncology, neurodegeneration, ophthalmology, and dermatology.
Business Model
SPARC operates as a research-driven entity, generating value through the development of proprietary pharmaceutical formulations and clinical-stage assets. It leverages collaboration agreements with global partners to identify small molecule leads and co-develop novel therapies.
Management Commentary
Management focuses on advancing a robust pipeline of clinical-stage candidates, including phase 3 trials for ophthalmic and neurological conditions. The company continues to prioritise strategic partnerships to accelerate the development of its diverse therapeutic portfolio.
Growth Outlook
Growth is driven by the progression of late-stage clinical assets such as SDN-037 and PDP-716, alongside ongoing research in oncology and autoimmune disorders. The company's ability to successfully commercialise its pipeline and secure further collaborative research agreements remains a key catalyst.
- Clinical Focus:Oncology, Neurodegeneration, Ophthalmology, Dermatology
Key Risks
- Clinical Trial Failure. The company faces significant risk that its pipeline candidates may fail to meet primary endpoints in clinical trials, leading to the loss of R&D investment.
- Regulatory Approval Risk. The commercialisation of new pharmaceutical products is subject to stringent regulatory scrutiny and approval processes in India and international markets.
- Intellectual Property Risk. The company's business model relies on the successful protection and enforcement of its intellectual property rights for novel chemical and biological entities.
- Funding and Capital Requirements. As a research-intensive company, SPARC requires sustained capital to fund long-term clinical development cycles before achieving consistent profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Sun Pharma Advanced Research Company Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,909 Cr
TTM · consolidated
NET PROFIT
₹1,584 Cr
TTM · consolidated
EPS
₹48.81
TTM · consolidated
RETURN ON EQUITY
282.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
235.1%
TTM · consolidated
P/E
4.1x
Q1 FY27 · consolidated
EV/EBITDA
4.3x
Q1 FY27 · consolidated
EBITDA MARGIN
86.0%
TTM · consolidated
NET PROFIT MARGIN
-52.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sun Pharma Advanced Research Company LimitedSPARC | ₹6,473 Cr | 4.09 | 4.28 | 2855.8% | 86.0% | 282.4% | 235.1% | +38.2% |
Supriya Lifescience LimitedSUPRIYA | ₹6,864 Cr | 34.60 | 22.66 | 28.1% | 34.5% | 18.1% | 23.8% | +30.1% |
Innova Captab LimitedINNOVACAP | ₹6,726 Cr | 43.68 | 26.28 | 34.5% | 15.4% | 15.0% | 17.4% | +27.9% |
Senores Pharmaceuticals Ltd.SENORES | ₹6,578 Cr | 50.30 | 29.26 | — | 34.7% | 15.2% | 18.4% | +102.9% |
Jeena Sikho Lifecare LimitedJSLL | ₹6,418 Cr | 27.15 | 16.65 | — | 45.2% | 50.6% | 58.2% | -33.7% |
Morepen Laboratories LimitedMOREPENLAB | ₹6,232 Cr | 44.43 | 31.03 | 9.5% | 10.6% | 11.7% | 14.4% | +129.7% |
As of Q1 FY27
Financials
Sun Pharma Advanced Research Company Limited
NSE: SPARC · Pharmaceuticals
Snapshot
Unlock Sun Pharma Advanced Research Company Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sun Pharma Advanced Research Company Limited (SPARC) is a biopharmaceutical firm focused on the research and development of new chemical and biological entities, as well as reformulated pharmaceutical products. The company specialises in therapeutic areas including oncology, neurodegeneration, ophthalmology, and dermatology.
Business Model
SPARC operates as a research-driven entity, generating value through the development of proprietary pharmaceutical formulations and clinical-stage assets. It leverages collaboration agreements with global partners to identify small molecule leads and co-develop novel therapies.
Management Commentary
Management focuses on advancing a robust pipeline of clinical-stage candidates, including phase 3 trials for ophthalmic and neurological conditions. The company continues to prioritise strategic partnerships to accelerate the development of its diverse therapeutic portfolio.
Growth Outlook
Growth is driven by the progression of late-stage clinical assets such as SDN-037 and PDP-716, alongside ongoing research in oncology and autoimmune disorders. The company's ability to successfully commercialise its pipeline and secure further collaborative research agreements remains a key catalyst.
- Clinical Focus:Oncology, Neurodegeneration, Ophthalmology, Dermatology
Key Risks
- Clinical Trial Failure. The company faces significant risk that its pipeline candidates may fail to meet primary endpoints in clinical trials, leading to the loss of R&D investment.
- Regulatory Approval Risk. The commercialisation of new pharmaceutical products is subject to stringent regulatory scrutiny and approval processes in India and international markets.
- Intellectual Property Risk. The company's business model relies on the successful protection and enforcement of its intellectual property rights for novel chemical and biological entities.
- Funding and Capital Requirements. As a research-intensive company, SPARC requires sustained capital to fund long-term clinical development cycles before achieving consistent profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Sun Pharma Advanced Research Company Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,909 Cr
TTM · consolidated
NET PROFIT
₹1,584 Cr
TTM · consolidated
EPS
₹48.81
TTM · consolidated
RETURN ON EQUITY
282.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
235.1%
TTM · consolidated
P/E
4.1x
Q1 FY27 · consolidated
EV/EBITDA
4.3x
Q1 FY27 · consolidated
EBITDA MARGIN
86.0%
TTM · consolidated
NET PROFIT MARGIN
-52.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27